Supplementary Figure 2 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure 2. Schematic showing how sipuleucel-T is designed to activate a patient's immune system by ex vivo cellular activation during manufacture and subsequent in vivo immune response.